Table 4.
Group | Blood glucose level (mg/dL) | |||
---|---|---|---|---|
0 min | 30 min | 60 min | 120 min | |
DW10 | 85.83 ± 2.23 | 186.33 ± 3.64 | 141.33 ± 4.36 | 114.33 ± 3.33 |
GLC5 | 89.17 ± 3.28 | 156.33 ± 3.95a3,β3 | 77.00 ± 6.23a3,μ3 | 73.33 ± 5.78a3,μ3 |
BAC100 | 84.17 ± 2.01 | 178.17 ± 1.07 β3,n2 | 137.17 ± 7.54 β3,n3,μ2 | 87.67 ± 8.53a1,μ3 |
BAC200 | 82.83 ± 2.6 | 169.50 ± 3.67a1,β3 | 113.33 ± 8.55a1,n2,β2,μ3 | 83.50 ± 2.69a2,μ3 |
BAC400 | 87.50 ± 4.01 | 160.83 ± 2.45a3,β3 | 91.17 ± 4.67a3,μ3 | 75.83 ± 3.99a3,μ3 |
Abbreviations: BAC, Bersama abyssinica leaf crude extract; DW, distilled water; GLC, glibenclamide.
* Each value represents mean ± SEM; n = 6 for each treatment. aCompared with the negative control, bcompared with BAC100, ccompared with BAC200, dcompared with BAC400, μcompared with the blood glucose level at 30 minutes and βcompared with baseline blood glucose level, ncompared with GLC5. 1 P < .05, 2 P < .01, 3 P < .001.